Healthy subjects will be randomized within one of the following sequential dose cohorts:
- LMN-101, six 500-mg capsules orally three times daily for 28 days (n=21), or identical-appearing placebo (n=7); or
- LMN-101, two 500-mg capsules and four 500-mg placebo capsules orally three times daily for
Hemolytic uremic syndrome (HUS) is defined by the combination of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. The underlying lesion is thrombotic microangiopathy (TMA) affecting arteriole and capillary walls, with endothelial cells swelling and detachment and thrombi